Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
DecImmune Therapeutics
AddedFeb 15, 2024
UpdatedJun 18, 2026
DecImmune Therapeutics

DecImmune Therapeutics

DecImmune Therapeutics develops biotech products for acute inflammation and vascular injury treatment.

HQ
Cambridge, MA, US
Founded
2001
Overview
Compare
Fundraising
Employees
Website

DecImmune Therapeutics, founded in Cambridge, United States, is a biotechnology company focused on developing innovative therapeutics for acute inflammation and vascular injury. The company's core mission is to prevent tissue damage and preserve organ function in conditions such as myocardial infarction and burns. DecImmune's flagship product, DeciMabâ„¢, is a novel monoclonal antibody designed to address a range of vascular inflammatory diseases. Their market focus includes healthcare providers and patients suffering from acute, tissue-damaging conditions across the United States.

Notable achievements for DecImmune Therapeutics include securing $3 million in SBIR Phase IIB funding and a partnership with DSM to develop an N2 pathway blocking antibody. These milestones underscore the company's progress in advancing its therapeutic pipeline. DecImmune's impact lies in its potential to significantly improve treatment outcomes for patients with severe inflammatory conditions, thereby addressing unmet medical needs and enhancing quality of life.

DecImmune Therapeutics - Similar Companies

Deciduous Therapeutics logo

Deciduous Therapeutics

deciduoustx.com

ImmuneXcite logo

ImmuneXcite

ImmuneSensor Therapeutics logo

ImmuneSensor Therapeutics

immunesensor.com

Deka Biosciences logo

Deka Biosciences

Inimmune logo

Inimmune

inimmune.com

MindImmune Therapeutics logo

MindImmune Therapeutics

mindimmune.com

Immvention Therapeutix logo

Immvention Therapeutix

Therini Bio logo

Therini Bio

therinibio.com

Immunomic Therapeutics logo

Immunomic Therapeutics

immunomix.com

DiaVacs logo

DiaVacs

diavacs.com

ImmunGene logo

ImmunGene

NeuImmune logo

NeuImmune

neuimmune.com

ImmuneTarget logo

ImmuneTarget

ImmuneID logo

ImmuneID

ImmuRx logo

ImmuRx

immurx.com

DecImmune Therapeutics - Quick Facts

Who are DecImmune Therapeutics' competitors?

Companies similar to DecImmune Therapeutics include Deciduous Therapeutics, ImmuneXcite, ImmuneSensor Therapeutics and Deka Biosciences.

When was DecImmune Therapeutics founded?

DecImmune Therapeutics was founded in 2001.

Where is DecImmune Therapeutics' headquarters located?

DecImmune Therapeutics' headquarters is located in Cambridge, MA, US.

When was DecImmune Therapeutics' last funding round?

DecImmune Therapeutics' most recent funding round was for $3M (USD) in October 2014.

How much has DecImmune Therapeutics raised to-date?

As of Oct 3, 2014, DecImmune Therapeutics has raised a total of $8.4M (USD).

How many employees does DecImmune Therapeutics have?

DecImmune Therapeutics has 7 employees as of Feb 5, 2024.

DecImmune Therapeutics - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Biotech Products
Tags
  • Healthcare
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified